It reported positive reports from clinical studies of the device, which will be incorporated into Proxima 3.
The studies took place in the UK and evaluated 105 blood sampled from 18 patients undergoing surgery.
The enhancements include usability improvements and a red blood cell percentage measure, the firm said.
The company says it is in "advanced preparations" for a CE marking - European regulatory approval - of the product.
The development comes after the firm announced a tie-up last month with Ortho Clinical Diagnostics (OCD), a subsidiary of Johnson & Johnson, for the development of the next version of the device - Proxima 4.
Sphere's chief executive Dr Stuart Hendry said today: "In this study we have demonstrated in a clinical setting a number of important system enhancements and usability improvements that will be implemented in the commercial Proxima 3 product.
"This additional study data contributes to the significant progress we have made with Proxima and we are now in advanced preparations for CE Marking of Proxima 3 which will enable us to launch Proxima 3 into the UK market in H1 2014."